Search research articles
Contact Us
Filters
Showing results (101-110 of 265) with videos related to
Page
of 27
Sort By:
Cancer Medicine
|
December 22, 2017
Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma
Jessica C Hassel, Kristina Buder-Bakhaya, Carolin Bender, et al.
Cancer
|
July 11, 2008
Combined treatment with pegylated interferon-alpha-2a and dacarbazine in patients with advanced metastatic melanoma: a phase 2 study
Axel Hauschild, Reinhard Dummer, Selma Ugurel, et al.
The Journal of Investigative Dermatology
|
March 11, 2011
ERCC5 p.Asp1104His and ERCC2 p.Lys751Gln polymorphisms are independent prognostic factors for the clinical course of melanoma
David Schrama, Dominique Scherer, Michael Schneider, et al.
Scientific Reports
|
May 25, 2017
Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma
Cathrin Ritter, Kaiji Fan, Annette Paschen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 4, 2020
Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study
Martin Salzmann, Ulrike Leiter, Carmen Loquai, et al.
Oncogene
|
October 23, 2025
High-resolution spatial transcriptomics uncover epidermal-dermal divergences in Merkel cell carcinoma: spatial context reshapes the gene expression landscape
Kuan Cheok Lei, Nalini Srinivas, Mitalee Chandra, et al.
Melanoma Research
|
July 16, 2008
Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma
Axel Hauschild, Uwe Trefzer, Claus Garbe, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
July 25, 2013
Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha-2b in metastatic melanoma (phase II DeCOG trial)
Annette Degen, Michael Weichenthal, Selma Ugurel, et al.
JAMA Dermatology
|
June 20, 2014
Presence of human polyomavirus 6 in mutation-specific BRAF inhibitor-induced epithelial proliferations
David Schrama, Leopold Groesser, Selma Ugurel, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
May 15, 2023
S1-Leitlinie dermales und subkutanes Leiomyosarkom
Doris Helbig, Edgar Dippel, Michael Erdmann, et al.
Page
of 27
Search research articles
Search
Showing results (101-110 of 265) with videos related to
Sort By:
Page
of 27
Cancer Medicine
|
December 22, 2017
Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma
Jessica C Hassel, Kristina Buder-Bakhaya, Carolin Bender, et al.
Cancer
|
July 11, 2008
Combined treatment with pegylated interferon-alpha-2a and dacarbazine in patients with advanced metastatic melanoma: a phase 2 study
Axel Hauschild, Reinhard Dummer, Selma Ugurel, et al.
The Journal of Investigative Dermatology
|
March 11, 2011
ERCC5 p.Asp1104His and ERCC2 p.Lys751Gln polymorphisms are independent prognostic factors for the clinical course of melanoma
David Schrama, Dominique Scherer, Michael Schneider, et al.
Scientific Reports
|
May 25, 2017
Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma
Cathrin Ritter, Kaiji Fan, Annette Paschen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 4, 2020
Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study
Martin Salzmann, Ulrike Leiter, Carmen Loquai, et al.
Oncogene
|
October 23, 2025
High-resolution spatial transcriptomics uncover epidermal-dermal divergences in Merkel cell carcinoma: spatial context reshapes the gene expression landscape
Kuan Cheok Lei, Nalini Srinivas, Mitalee Chandra, et al.
Melanoma Research
|
July 16, 2008
Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma
Axel Hauschild, Uwe Trefzer, Claus Garbe, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
July 25, 2013
Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha-2b in metastatic melanoma (phase II DeCOG trial)
Annette Degen, Michael Weichenthal, Selma Ugurel, et al.
JAMA Dermatology
|
June 20, 2014
Presence of human polyomavirus 6 in mutation-specific BRAF inhibitor-induced epithelial proliferations
David Schrama, Leopold Groesser, Selma Ugurel, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
May 15, 2023
S1-Leitlinie dermales und subkutanes Leiomyosarkom
Doris Helbig, Edgar Dippel, Michael Erdmann, et al.
Page
of 27